Christoph Rader from Jupiter, FL, age 60

A33 Antigen Specific Immunoglobulin Products And Uses Thereof
view source
US Patent:

6342587, Jan 29, 2002
Filed:

Oct 22, 1999
Appl. No.:

09/425638
Inventors:

Christoph Rader - San Diego CA
Gerd Ritter - New York NY
Sydney Welt - New York NY
Lloyd J. Old - New York NY
Assignee:

Ludwig Institute for Cancer Research - New York NY
The Scripps Research Institute - La Jolla CA
International Classification:

C07K 1628
US Classification:

53038885, 5303888, 5303873, 4241301, 4241331, 4241561
Abstract:

The invention is directed to novel CDRs and immunoglobulin products that bind to A33 antigens and methods for their use. The invention also involves a method for making humanized antibodies, using a rabbit as a host animal, and phage display library methodologies, and the antibodies themselves. The methodology is useful, for example, in generating humanized antibodies against molecules associated with cancer, such as A33, which is associated with colon cancer.

Methods For Reducing The Effects Of Cancers That Express A33 Antigen Using A33 Antigen Specific Immunoglobulin Products
view source
US Patent:

6346249, Feb 12, 2002
Filed:

Apr 4, 2000
Appl. No.:

09/543004
Inventors:

Christoph Rader - San Diego CA
Gerd Ritter - New York NY
Sydney Welt - New York NY
Lloyd J. Old - New York NY
Assignee:

Ludwig Institute for Cancer Research - New York NY
The Scripps Research Institute - La Jolla CA
International Classification:

A61K 39395
US Classification:

4241811, 4241301, 4241561, 4241831, 5303888, 53038885, 5303897
Abstract:

The invention is directed to methods of reducing the effects of cancer in a subject by administering to said subject a pharmaceutically effective amount of an anti-cancer agent conjugated to an inmmunoglobulin product which comprises one or more novel complementarity determining region and framework regions.

Prodrug Activation Using Catalytic Antibodies
view source
US Patent:

6677435, Jan 13, 2004
Filed:

Jun 18, 2001
Appl. No.:

09/883758
Inventors:

Doron Shabat - Tel Aviv, IL
Christoph Rader - San Diego CA
Benjamin List - San Diego CA
Richard A. Lerner - La Jolla CA
Assignee:

The Scripps Research Institute - La Jolla CA
International Classification:

C07K 1600
US Classification:

5303871, 5303911
Abstract:

The present invention provides a compound that includes an active therapeutic agent attached to a blocking moiety that is sensitive to the catalytic action of molecules having retro-aldol and retro-Michael catalytic activity, methods for making such compounds and methods of converting such compounds to active therapeutic agents using molecules having aldolase activity.

Humanization Of Murine Antibody
view source
US Patent:

7087409, Aug 8, 2006
Filed:

Feb 19, 2002
Appl. No.:

10/078757
Inventors:

Christoph Rader - San Diego CA, US
Assignee:

The Scripps Research Institute - La Jolla CA
International Classification:

C12P 21/04
C12Q 1/70
C12P 21/08
C07K 16/00
C07H 21/04
US Classification:

435 696, 435 5, 4352351, 4353201, 5303873, 5303881, 53038823, 536 2353
Abstract:

A humanized murine antibody is provided. The amino acid sequences of a light chain complementarity determining region from a mouse antibody are grafted onto a human light chain, and a heavy chain complementarity determining region from a mouse antibody are grafted onto a human antibody heavy chain to produce libraries from which a humanized murine antibody having the desired specificity is selected.

Antibody Targeting Compounds
view source
US Patent:

8252902, Aug 28, 2012
Filed:

Oct 22, 2002
Appl. No.:

10/278364
Inventors:

Carlos F. Barbas - Solana Beach CA, US
Christoph Rader - San Diego CA, US
Subhash C. Sinha - San Diego CA, US
Richard A. Lerner - La Jolla CA, US
Assignee:

The Scripps Research Institute - La Jolla CA
International Classification:

C07K 16/00
US Classification:

5303871, 424 934, 4241301, 4241781, 4241791
Abstract:

The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.

Integrin Targeting Compounds
view source
US Patent:

20030129188, Jul 10, 2003
Filed:

Oct 22, 2002
Appl. No.:

10/278539
Inventors:

Carlos Barbas - Solana Beach CA, US
Christoph Rader - San Diego CA, US
Subhash Sinha - San Diego CA, US
Assignee:

The Scripps Research Institute
International Classification:

A61K039/395
A61K031/5513
A61K031/55
C 07D 4 3/14
C07K016/28
US Classification:

424/144100, 514/212070, 514/221000, 530/388220, 540/500000, 540/523000
Abstract:

The present invention is directed to integrin targeting compounds comprising an integrin targeting component linked to a functional component such as a therapeutic agent or antibody. Structures of various integrin targeting compounds are provided. Additionally provided are methods of delivering a functional component to integrin associated with cells or tissue of an individual using the integrin targeting compounds. Also provided are methods of treating or preventing a disease or condition in an individual using the wherein said disease or condition involves an integrin using the integrin targeting compounds.

Antibody Targeting Compounds
view source
US Patent:

20030190676, Oct 9, 2003
Filed:

Apr 21, 2003
Appl. No.:

10/420373
Inventors:

Carlos Barbas - Solana Beach CA, US
Christoph Rader - San Diego CA, US
Subhash Sinha - San Diego CA, US
Richard Lerner - La Jolla CA, US
Assignee:

The Scripps Research Institute - La Jolla CA
International Classification:

G01N033/53
A61K039/395
A61K038/05
C12N009/00
US Classification:

435/007100, 435/188500, 514/018000, 424/130100
Abstract:

The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.

Selenocysteine Mediated Hybrid Antibody Molecules
view source
US Patent:

20100104510, Apr 29, 2010
Filed:

Sep 30, 2009
Appl. No.:

12/570796
Inventors:

Christoph Rader - Olney MD, US
Thomas Hofer - Zurich, CH
Terrence Burke, JR. - Bethesda MD, US
Joshua Thomas - Frederick MD, US
Assignee:

Services - Bethesda MD
International Classification:

A61K 51/00
A61K 39/395
C12P 21/06
C12N 5/071
A61P 35/04
A61P 25/00
C12N 5/02
US Classification:

424 149, 4241781, 435 691, 435366, 435372, 4353721, 435375
Abstract:

The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.